Patients receive Pemetrexed 500mg/m2 day1 + Carboplatin AUC6 day1 + Bevacizumab 15mg/kg day1, q3w, 4-6 cycles. Patients who achieved disease control receive Pemetrexed 500mg/m2 day1 + Bevacizumab 15

2 trials

Sponsors

Central Japan Lung Study Group

Conditions

Advanced non-squamous non-small cell lung cancer with EGFR MutationAdvanced non-squamous non-small cell lung cancer without EGFR Mutation

Phase 2

Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer without EGFR Mutation (CJLSG0909)

Active, not recruitingJPRN-UMIN000003736

Central Japan Lung Study GroupAdvanced non-squamous non-small cell lung cancer without EGFR Mutation

Start: 2010-06-01Target: 52Updated: 2026-06-29

Unknown Phase

Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)

Active, not recruitingJPRN-UMIN000003737

Central Japan Lung Study GroupAdvanced non-squamous non-small cell lung cancer with EGFR Mutation

Start: 2010-06-01Target: 32Updated: 2026-06-29

Related Papers

Pemetrexed (Pem), carboplatin (Cb), and bevacizumab (Bev) in patients with nonsquamous NSCLC without or with activating EGFR mutation (CJLSG0909/0910).

Journal of Clinical Oncology2015-05-20